Details of the Drug

General Information of Drug (ID: DMODJ40)

Drug Name
Ethinyl Estradiol
Synonyms
Aethinyloestradiolum; Aethinyoestradiol; Amenoron; Amenorone; Anovlar; Certostat; Cyclosa; Dicromil; Diprol; Dyloform; Ertonyl; Esteed; Estigyn; Estinyl; Estopherol; Estoral; Estorals; Ethidol; Ethinoral; Ethinylestradiolum; Ethinylestriol; Ethinyloestradiol; Ethynylestradiol; Ethynyloestradiol; Eticyclin; Eticyclol; Eticylol; Etinestrol; Etinestryl; Etinilestradiol; Etinilestradiolo; Etinoestryl; Etistradiol; Etivex; Feminone; Follicoral; Ginestrene; Inestra; Kolpolyn; Linoral; Lynoral; Menolyn; Microfollin; Novestrol; Oradiol; Orestralyn; Orestrayln; Palonyl; Perovex; Primogyn; Prosexol; Spanestrin; Ylestrol; Aethinyoestradiol [German]; Component of Demulen; Component of Oracon; Component of Ortrel; Diogyn E; Effik Brand of Ethinyl Estradiol; Estoral [Orion]; Ethinyl Estradiol Hemihydrate; Ethinyl Estradiol [USP]; Ethinyl Oestradiol Effik; Ethinylestradiol Jenapharm; Ethinyloestradiol [Steroidal oestrogens]; Ethynyl estradiol; Etinilestradiolo [DCIT]; Jenapharm Brand of Ethinyl Estradiol; Microfollin Forte; Organon Brand of Ethinyl Estradiol; PUBERTAL ETHINYL ESTRADIOL STUDY; Primogyn C; Primogyn M; Progynon C; Progynon M; Schering Brand of Ethinyl Estradiol; EE2; Ethinyl E2; Ethy 11; Diognat-E; Diogyn-E; EE(sub 2); Estinyl (TN); Eston-E; Estoral (Orion); Estoral (VAN); Estradiol, Ethinyl; Estradiol, Ethynyl; Ethinyl estradiol (USP); Ethinyl-Oestradiol Effik; Ethinyl-oestranol; Ethinylestradiolum [INN-Latin]; Ethynylestradiol, Ethinyl Estradiol; Etinilestradiol [INN-Spanish]; Hemihydrate, Ethinyl Estradiol; Jenapharm, Ethinylestradiol; Neo-Estrone; Nogest-S; OVULEN-21; OVULEN-28; Ortho-Cyclen; Chee-O-Gen; Chee-O-Genf; Ethinylestradiol (JP15/INN); Ethinylestradiol [INN:BAN:JAN]; Ethinyl Estradiol, (8 alpha)-Isomer; 17 alpha-Ethinylestradiol; 17 alpha-Ethynylestradiol; 17 alpha-Ethynyloestradiol; 17 alpha-ethinyestradiol; 17-Ethinyl-3,17-estradiol; 17-Ethinyl-3,17-oestradiol; 17-Ethinylestradiol; 17-Ethynylestradiol; 17-Ethynyloestradiol; 17-alpha-Ethinyl-17-beta-estradiol; 17-alpha-Ethynyl-17-beta-oestradiol; 17-alpha-Ethynylestradiol; 17-alpha-Ethynylestradiol-17-beta; 17-alpha-Ethynylestradiol-l7-beta; 17-alpha-Ethynyloestradiol-17-beta; 17-alpha-ethynyl estradiol; 17.alpha.-Ethinyl-17.beta.-estradiol; 17.alpha.-Ethinylestradiol; 17.alpha.-Ethynyl-17.beta.-oestradiol; 17.alpha.-Ethynylestradiol; 17.alpha.-Ethynyloestradiol; 17a-Ethynylestradiol; 17alpha-Ethinyl estradiol; 17alpha-Ethinylestradiol; 17alpha-Ethinylestradiol-17beta; 17alpha-Ethynylestradiol; 17alpha-Ethynyloestradiol; 17alpha-Ethynyloestradiol-17beta
Indication
Disease Entry ICD 11 Status REF
Acne vulgaris ED80 Approved [1]
Female hypogonadism GA30.6 Approved [2]
Hot flushes GA30 Approved [1]
Obsolete atrophic vulva N.A. Approved [1]
Therapeutic Class
Estrogens
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 296.4
Logarithm of the Partition Coefficient (xlogp) 3.7
Rotatable Bond Count (rotbonds) 1
Hydrogen Bond Donor Count (hbonddonor) 2
Hydrogen Bond Acceptor Count (hbondacc) 2
ADMET Property
Absorption AUC
The area under the plot of plasma concentration (AUC) of drug is 0.4874 +/- 0.1666 mcgh/L [3]
Absorption Cmax
The maximum plasma concentration (Cmax) of drug is 74.1 +/- 35.6 ng/L [3]
Absorption Tmax
The time to maximum plasma concentration (Tmax) is 1.5 +/- 0.5 h [3]
BDDCS Class
Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 1: high solubility and high permeability [4]
Clearance
The renal clearance of drug is 2.1 L/h [5]
Elimination
Ethinylestradiol is 59.2% eliminated in the urine and bile, while 2-3% is eliminated in the feces, and over 90% of ethinylestradiol is eliminated as the unchanged parent drug [6]
Half-life
The concentration or amount of drug in body reduced by one-half in 27.7 +/- 34.2 hours [3]
Metabolism
The drug is metabolized via UGT1A1, UGT1A3, UGT1A4, UGT1A9, and UGT2B7 [7]
MRTD
The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 0.09639 micromolar/kg/day [8]
Unbound Fraction
The unbound fraction of drug in plasma is 0.014% [9]
Vd
The volume of distribution (Vd) of drug is 625.3 +/- 228.7 L [3]
Adverse Drug Reaction (ADR)
ADR Term Variation Related DOT DOT ID REF
Hepatotoxicity Not Available CYP2B OTDDG81I [10]
Hepatotoxicity Not Available FGF4 OTNVV3ZG [10]
Chemical Identifiers
Formula
C20H24O2
IUPAC Name
(8R,9S,13S,14S,17R)-17-ethynyl-13-methyl-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthrene-3,17-diol
Canonical SMILES
C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@]2(C#C)O)CCC4=C3C=CC(=C4)O
InChI
InChI=1S/C20H24O2/c1-3-20(22)11-9-18-17-6-4-13-12-14(21)5-7-15(13)16(17)8-10-19(18,20)2/h1,5,7,12,16-18,21-22H,4,6,8-11H2,2H3/t16-,17-,18+,19+,20+/m1/s1
InChIKey
BFPYWIDHMRZLRN-SLHNCBLASA-N
Cross-matching ID
PubChem CID
5991
ChEBI ID
CHEBI:4903
CAS Number
57-63-6
DrugBank ID
DB00977
TTD ID
D06NXY
VARIDT ID
DR00103
INTEDE ID
DR0656
Combinatorial Drugs (CBD) Click to Jump to the Detailed CBD Information of This Drug
Repurposed Drugs (RPD) Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Estrogen receptor (ESR) TTZAYWL ESR1_HUMAN Agonist [11]

Drug Transporter (DTP)
DTP Name DTP ID UniProt ID MOA REF
P-glycoprotein 1 (ABCB1) DTUGYRD MDR1_HUMAN Substrate [12]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Cytochrome P450 3A4 (CYP3A4) DE4LYSA CP3A4_HUMAN Substrate [13]
Cytochrome P450 2C9 (CYP2C9) DE5IED8 CP2C9_HUMAN Substrate [14]
Cytochrome P450 1A1 (CYP1A1) DE6OQ3W CP1A1_HUMAN Substrate [14]
UDP-glucuronosyltransferase 1A1 (UGT1A1) DEYGVN4 UD11_HUMAN Substrate [15]
Mephenytoin 4-hydroxylase (CYP2C19) DEGTFWK CP2CJ_HUMAN Substrate [16]
Cytochrome P450 2C8 (CYP2C8) DES5XRU CP2C8_HUMAN Substrate [17]

Drug Off-Target (DOT)
DOT Name DOT ID UniProt ID Interaction REF
4-aminobutyrate aminotransferase, mitochondrial (ABAT) OTXAGR7J GABT_HUMAN Gene/Protein Processing [18]
A disintegrin and metalloproteinase with thrombospondin motifs 9 (ADAMTS9) OTV3Q0DS ATS9_HUMAN Gene/Protein Processing [18]
Activin receptor type-1B (ACVR1B) OT778HIQ ACV1B_HUMAN Gene/Protein Processing [18]
Adiponectin (ADIPOQ) OTNX23LE ADIPO_HUMAN Gene/Protein Processing [18]
ADP-ribosylation factor 3 (ARF3) OTYYQX85 ARF3_HUMAN Gene/Protein Processing [18]
Advanced glycosylation end product-specific receptor (AGER) OTPY0IH7 RAGE_HUMAN Gene/Protein Processing [19]
Aldehyde dehydrogenase 1A1 (ALDH1A1) OTCUWZKB AL1A1_HUMAN Gene/Protein Processing [18]
Alkaline phosphatase, germ cell type (ALPG) OTCIM29R PPBN_HUMAN Gene/Protein Processing [18]
Alkaline phosphatase, placental type (ALPP) OTZU4G9W PPB1_HUMAN Gene/Protein Processing [18]
Amino acid transporter heavy chain SLC3A1 (SLC3A1) OT56V01A SLC31_HUMAN Gene/Protein Processing [18]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Acne vulgaris
ICD Disease Classification ED80
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
P-glycoprotein 1 (ABCB1) DTP P-GP 7.23E-01 -8.20E-02 -3.22E-01
UDP-glucuronosyltransferase 1A1 (UGT1A1) DME UGT1A1 7.69E-01 1.91E-02 5.45E-02
Cytochrome P450 2C8 (CYP2C8) DME CYP2C8 9.78E-01 -3.38E-03 -5.71E-02
Mephenytoin 4-hydroxylase (CYP2C19) DME CYP2C19 3.44E-01 -1.85E-01 -5.25E-01
Cytochrome P450 1A1 (CYP1A1) DME CYP1A1 5.01E-01 -1.01E-02 -6.05E-02
Cytochrome P450 2C9 (CYP2C9) DME CYP2C9 9.09E-01 -9.26E-02 -3.68E-01
Cytochrome P450 3A4 (CYP3A4) DME CYP3A4 9.85E-01 2.24E-02 7.33E-02
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Ethinyl Estradiol (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Sarecycline DMLZNIQ Moderate Decreased absorption of Ethinyl estradiol due to formation of complexes caused by Sarecycline . Acne vulgaris [ED80] [20]
Metreleptin DM1NOEK Moderate Decreased metabolism of Ethinyl estradiol caused by Metreleptin mediated inhibition of CYP450 enzyme. Acute diabete complication [5A2Y] [21]
Pioglitazone DMKJ485 Minor Increased metabolism of Ethinyl estradiol caused by Pioglitazone mediated induction of CYP450 enzyme. Acute diabete complication [5A2Y] [22]
Ivosidenib DM8S6T7 Moderate Increased metabolism of Ethinyl estradiol caused by Ivosidenib mediated induction of CYP450 enzyme. Acute myeloid leukaemia [2A60] [23]
Emapalumab DMZG5WL Moderate Altered metabolism of Ethinyl estradiol due to Emapalumab alters the formation of CYP450 enzymes. Adaptive immunity immunodeficiency [4A01] [24]
Siltuximab DMGEATB Moderate Altered metabolism of Ethinyl estradiol due to Siltuximab alters the formation of CYP450 enzymes. Anemia [3A00-3A9Z] [24]
Dronedarone DMA8FS5 Moderate Decreased metabolism of Ethinyl estradiol caused by Dronedarone mediated inhibition of CYP450 enzyme. Angina pectoris [BA40] [25]
Posaconazole DMUL5EW Moderate Decreased metabolism of Ethinyl estradiol caused by Posaconazole mediated inhibition of CYP450 enzyme. Aspergillosis [1F20] [26]
Aminophylline DML2NIB Moderate Decreased metabolism of Ethinyl estradiol caused by Aminophylline. Asthma [CA23] [27]
Desipramine DMT2FDC Minor Decreased metabolism of Ethinyl estradiol caused by Desipramine. Attention deficit hyperactivity disorder [6A05] [28]
Ofloxacin DM0VQN3 Moderate Decreased absorption of Ethinyl estradiol due to formation of complexes caused by Ofloxacin. Bacterial infection [1A00-1C4Z] [20]
Clarithromycin DM4M1SG Moderate Decreased metabolism of Ethinyl estradiol caused by Clarithromycin mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [29]
Sparfloxacin DMB4HCT Moderate Decreased absorption of Ethinyl estradiol due to formation of complexes caused by Sparfloxacin. Bacterial infection [1A00-1C4Z] [20]
Gemifloxacin DMHT34O Moderate Decreased absorption of Ethinyl estradiol due to formation of complexes caused by Gemifloxacin. Bacterial infection [1A00-1C4Z] [20]
Norfloxacin DMIZ6W2 Moderate Decreased absorption of Ethinyl estradiol due to formation of complexes caused by Norfloxacin. Bacterial infection [1A00-1C4Z] [20]
ABT-492 DMJFD2I Moderate Decreased absorption of Ethinyl estradiol due to formation of complexes caused by ABT-492. Bacterial infection [1A00-1C4Z] [20]
Omadacycline DMR2J95 Moderate Decreased absorption of Ethinyl estradiol due to formation of complexes caused by Omadacycline. Bacterial infection [1A00-1C4Z] [20]
Levofloxacin DMS60RB Moderate Decreased absorption of Ethinyl estradiol due to formation of complexes caused by Levofloxacin. Bacterial infection [1A00-1C4Z] [20]
Minocycline DMVN5OH Moderate Decreased absorption of Ethinyl estradiol due to formation of complexes caused by Minocycline. Bacterial infection [1A00-1C4Z] [20]
Lomefloxacin DMVRH9C Moderate Decreased absorption of Ethinyl estradiol due to formation of complexes caused by Lomefloxacin. Bacterial infection [1A00-1C4Z] [20]
Ag-221 DMS0ZBI Moderate Decreased metabolism of Ethinyl estradiol caused by Ag-221 mediated inhibition of CYP450 enzyme. BCR-ABL1-negative chronic myeloid leukaemia [2A41] [21]
Pexidartinib DMS2J0Z Major Increased metabolism of Ethinyl estradiol caused by Pexidartinib mediated induction of CYP450 enzyme. Bone/articular cartilage neoplasm [2F7B] [30]
Lapatinib DM3BH1Y Moderate Decreased clearance of Ethinyl estradiol due to the transporter inhibition by Lapatinib. Breast cancer [2C60-2C6Y] [31]
Tucatinib DMBESUA Moderate Decreased metabolism of Ethinyl estradiol caused by Tucatinib mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [32]
Atorvastatin DMF28YC Minor Decreased metabolism of Ethinyl estradiol caused by Atorvastatin mediated inhibition of CYP450 enzyme. Cardiovascular disease [BA00-BE2Z] [33]
Anisindione DM2C48U Moderate Antagonize the effect of Ethinyl estradiol when combined with Anisindione. Coagulation defect [3B10] [34]
Oxtriphylline DMLHSE3 Moderate Decreased metabolism of Ethinyl estradiol caused by Oxtriphylline. Cough [MD12] [27]
Lumacaftor DMCLWDJ Major Increased metabolism of Ethinyl estradiol caused by Lumacaftor mediated induction of CYP450 enzyme. Cystic fibrosis [CA25] [35]
Ivacaftor DMZC1HS Moderate Decreased metabolism of Ethinyl estradiol caused by Ivacaftor mediated inhibition of CYP450 enzyme. Cystic fibrosis [CA25] [36]
Nefazodone DM4ZS8M Moderate Decreased metabolism of Ethinyl estradiol caused by Nefazodone mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [37]
Selegiline DM6034S Moderate Decreased metabolism of Ethinyl estradiol caused by Selegiline mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [38]
Clomipramine DMINRKW Minor Decreased metabolism of Ethinyl estradiol caused by Clomipramine. Depression [6A70-6A7Z] [28]
Doxepin DMPI98T Minor Decreased metabolism of Ethinyl estradiol caused by Doxepin. Depression [6A70-6A7Z] [28]
Cenobamate DM8KLU9 Moderate Increased metabolism of Ethinyl estradiol caused by Cenobamate mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [39]
Stiripentol DMMSDOY Moderate Decreased metabolism of Ethinyl estradiol caused by Stiripentol mediated inhibition of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [40]
Fosphenytoin DMOX3LB Major Increased metabolism of Ethinyl estradiol caused by Fosphenytoin mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [41]
Brivaracetam DMSEPK8 Minor Increased metabolism of Ethinyl estradiol caused by Brivaracetam mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [42]
Rufinamide DMWE60C Moderate Increased metabolism of Ethinyl estradiol caused by Rufinamide mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [35]
Phenobarbital DMXZOCG Major Increased metabolism of Ethinyl estradiol caused by Phenobarbital mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [41]
Eslicarbazepine DMZREFQ Major Increased metabolism of Ethinyl estradiol caused by Eslicarbazepine mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [41]
Dantrolene DM1D8XY Major Increased risk of hepatotoxicity by the combination of Ethinyl estradiol and Dantrolene. Fever [MG26] [43]
Tazemetostat DMWP1BH Moderate Increased metabolism of Ethinyl estradiol caused by Tazemetostat mediated induction of CYP450 enzyme. Follicular lymphoma [2A80] [23]
Itraconazole DMCR1MV Moderate Decreased metabolism of Ethinyl estradiol caused by Itraconazole mediated inhibition of CYP450 enzyme. Fungal infection [1F29-1F2F] [26]
Ketoconazole DMPZI3Q Moderate Decreased metabolism of Ethinyl estradiol caused by Ketoconazole mediated inhibition of CYP450 enzyme. Fungal infection [1F29-1F2F] [26]
Sulfinpyrazone DMEV954 Moderate Increased metabolism of Ethinyl estradiol caused by Sulfinpyrazone mediated induction of CYP450 enzyme. Gout [FA25] [39]
Boceprevir DMBSHMF Major Increased metabolism of Ethinyl estradiol caused by Boceprevir mediated induction of CYP450 enzyme. Hepatitis virus infection [1E50-1E51] [44]
ABT-450 DMFW860 Major Decreased metabolism of Ethinyl estradiol caused by ABT-450 mediated inhibition of UGT. Hepatitis virus infection [1E50-1E51] [29]
Telaprevir DMMRV29 Major Increased metabolism of Ethinyl estradiol caused by Telaprevir mediated induction of CYP450 enzyme. Hepatitis virus infection [1E50-1E51] [44]
Rifampin DMA8J1G Major Increased metabolism of Ethinyl estradiol caused by Rifampin mediated induction of CYP450 enzyme. HIV-infected patients with tuberculosis [1B10-1B14] [45]
Rifapentine DMCHV4I Major Increased metabolism of Ethinyl estradiol caused by Rifapentine mediated induction of CYP450 enzyme. HIV-infected patients with tuberculosis [1B10-1B14] [45]
Atazanavir DMSYRBX Moderate Decreased metabolism of Ethinyl estradiol caused by Atazanavir mediated inhibition of UGT. Human immunodeficiency virus disease [1C60-1C62] [21]
BMS-201038 DMQTAGO Moderate Decreased metabolism of Ethinyl estradiol caused by BMS-201038 mediated inhibition of CYP450 enzyme. Hyper-lipoproteinaemia [5C80] [23]
Pirfenidone DM6VZFQ Moderate Decreased metabolism of Ethinyl estradiol caused by Pirfenidone mediated inhibition of CYP450 enzyme. Idiopathic interstitial pneumonitis [CB03] [35]
Lesinurad DMUR64T Moderate Increased metabolism of Ethinyl estradiol caused by Lesinurad mediated induction of CYP450 enzyme. Inborn purine/pyrimidine/nucleotide metabolism error [5C55] [21]
Berotralstat DMWA2DZ Moderate Decreased metabolism of Ethinyl estradiol caused by Berotralstat mediated inhibition of CYP450 enzyme. Innate/adaptive immunodeficiency [4A00] [46]
Amobarbital DM0GQ8N Moderate Increased metabolism of Ethinyl estradiol caused by Amobarbital mediated induction of CYP450 enzyme. Insomnia [7A00-7A0Z] [39]
Melatonin DMKWFBT Minor Decreased metabolism of Ethinyl estradiol caused by Melatonin mediated inhibition of CYP450 enzyme. Insomnia [7A00-7A0Z] [29]
Linaclotide DM4EGV0 Moderate Altered absorption of Ethinyl estradiol caused by Linaclotide. Irritable bowel syndrome [DD91] [35]
Miltefosine DMND304 Moderate Altered absorption of Ethinyl estradiol caused by Miltefosine. Leishmaniasis [1F54] [21]
Glycerol phenylbutyrate DMDGRQO Moderate Increased metabolism of Ethinyl estradiol caused by Glycerol phenylbutyrate mediated induction of CYP450 enzyme. Liver disease [DB90-DB9Z] [35]
Brigatinib DM7W94S Major Increased metabolism of Ethinyl estradiol caused by Brigatinib mediated induction of CYP450 enzyme. Lung cancer [2C25] [23]
Lurbinectedin DMEFRTZ Moderate Decreased metabolism of Ethinyl estradiol caused by Lurbinectedin mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [47]
PF-06463922 DMKM7EW Moderate Increased metabolism of Ethinyl estradiol caused by PF-06463922 mediated induction of CYP450 enzyme. Lung cancer [2C25] [39]
Selpercatinib DMZR15V Moderate Decreased metabolism of Ethinyl estradiol caused by Selpercatinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [48]
Artemether DM48QOT Moderate Increased metabolism of Ethinyl estradiol caused by Artemether mediated induction of CYP450 enzyme. Malaria [1F40-1F45] [44]
Calaspargase pegol DMQZBXI Moderate Decreased metabolism of Ethinyl estradiol caused by Calaspargase pegol mediated hepatotoxicity. Malignant haematopoietic neoplasm [2B33] [29]
IPI-145 DMWA24P Moderate Decreased metabolism of Ethinyl estradiol caused by IPI-145 mediated inhibition of CYP450 enzyme. Mature B-cell leukaemia [2A82] [49]
Vemurafenib DM62UG5 Moderate Increased metabolism of Ethinyl estradiol caused by Vemurafenib mediated induction of CYP450 enzyme. Melanoma [2C30] [39]
LGX818 DMNQXV8 Major Increased metabolism of Ethinyl estradiol caused by LGX818 mediated induction of CYP450 enzyme. Melanoma [2C30] [23]
Dabrafenib DMX6OE3 Major Increased metabolism of Ethinyl estradiol caused by Dabrafenib mediated induction of CYP450 enzyme. Melanoma [2C30] [44]
Exjade DMHPRWG Moderate Increased metabolism of Ethinyl estradiol caused by Exjade mediated induction of CYP450 enzyme. Mineral absorption/transport disorder [5C64] [23]
Carfilzomib DM48K0X Major Additive thrombogenic effects by the combination of Ethinyl estradiol and Carfilzomib. Multiple myeloma [2A83] [44]
Romidepsin DMT5GNL Moderate Antagonize the effect of Ethinyl estradiol when combined with Romidepsin. Mycosis fungoides [2B01] [43]
Fedratinib DM4ZBK6 Moderate Decreased metabolism of Ethinyl estradiol caused by Fedratinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [21]
Dasatinib DMJV2EK Moderate Decreased metabolism of Ethinyl estradiol caused by Dasatinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [29]
E-2007 DMJDYNQ Moderate Increased metabolism of Ethinyl estradiol caused by E-2007 mediated induction of CYP450 enzyme. Neuropathy [8C0Z] [35]
Olaparib DM8QB1D Moderate Increased metabolism of Ethinyl estradiol caused by Olaparib mediated induction of CYP450 enzyme. Ovarian cancer [2C73] [35]
Rucaparib DM9PVX8 Moderate Decreased metabolism of Ethinyl estradiol caused by Rucaparib mediated inhibition of CYP450 enzyme. Ovarian cancer [2C73] [50]
Abametapir DM2RX0I Moderate Decreased metabolism of Ethinyl estradiol caused by Abametapir mediated inhibition of CYP450 enzyme. Pediculosis [1G00] [51]
Lefamulin DME6G97 Moderate Decreased metabolism of Ethinyl estradiol caused by Lefamulin mediated inhibition of CYP450 enzyme. Pneumonia [CA40] [31]
Lonafarnib DMGM2Z6 Moderate Decreased metabolism of Ethinyl estradiol caused by Lonafarnib mediated inhibition of CYP450 enzyme. Premature ageing appearance [LD2B] [52]
Ustekinumab DMHTYK3 Moderate Altered metabolism of Ethinyl estradiol due to Ustekinumab alters the formation of CYP450 enzymes. Psoriasis [EA90] [24]
Ixekizumab DMXW92T Moderate Altered metabolism of Ethinyl estradiol due to Ixekizumab alters the formation of CYP450 enzymes. Psoriasis [EA90] [24]
Temsirolimus DMS104F Moderate Increased plasma concentrations of Ethinyl estradiol and Temsirolimus due to competitive inhibition of the same metabolic pathway. Renal cell carcinoma [2C90] [53]
Gatifloxacin DMSL679 Moderate Decreased absorption of Ethinyl estradiol due to formation of complexes caused by Gatifloxacin. Respiratory infection [CA07-CA4Z] [20]
Tocilizumab DM7J6OR Moderate Altered metabolism of Ethinyl estradiol due to Tocilizumab alters the formation of CYP450 enzymes. Rheumatoid arthritis [FA20] [24]
Canakinumab DM8HLO5 Moderate Altered metabolism of Ethinyl estradiol due to Canakinumab alters the formation of CYP450 enzymes. Rheumatoid arthritis [FA20] [24]
Rilonacept DMGLUQS Moderate Altered metabolism of Ethinyl estradiol due to Rilonacept alters the formation of CYP450 enzymes. Rheumatoid arthritis [FA20] [24]
Golimumab DMHZV7X Moderate Altered metabolism of Ethinyl estradiol due to Golimumab alters the formation of CYP450 enzymes. Rheumatoid arthritis [FA20] [24]
Sarilumab DMOGNXY Moderate Altered metabolism of Ethinyl estradiol due to Sarilumab alters the formation of CYP450 enzymes. Rheumatoid arthritis [FA20] [24]
Voxelotor DMCS6M5 Moderate Decreased metabolism of Ethinyl estradiol caused by Voxelotor mediated inhibition of CYP450 enzyme. Sickle-cell disorder [3A51] [21]
Telotristat ethyl DMDIYFZ Moderate Increased metabolism of Ethinyl estradiol caused by Telotristat ethyl mediated induction of CYP450 enzyme. Small intestine developmental anomaly [DA90] [35]
Larotrectinib DM26CQR Moderate Decreased metabolism of Ethinyl estradiol caused by Larotrectinib mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [29]
Armodafinil DMGB035 Moderate Increased metabolism of Ethinyl estradiol caused by Armodafinil mediated induction of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [44]
Pitolisant DM8RFNJ Moderate Increased metabolism of Ethinyl estradiol caused by Pitolisant mediated induction of CYP450 enzyme. Somnolence [MG42] [35]
Fostamatinib DM6AUHV Moderate Decreased clearance of Ethinyl estradiol due to the transporter inhibition by Fostamatinib. Thrombocytopenia [3B64] [54]
⏷ Show the Full List of 96 DDI Information of This Drug

References

1 Ethinyl estradiol FDA Label
2 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7071).
3 An open-label, two-period comparative study on pharmacokinetics and safety of a combined ethinylestradiol/gestodene transdermal contraceptive patch. Drug Des Devel Ther. 2017 Mar 10;11:725-731. doi: 10.2147/DDDT.S131123. eCollection 2017.
4 BDDCS applied to over 900 drugs
5 Ezuruike U, Humphries H, Dickins M, Neuhoff S, Gardner I, Rowland Yeo K: Risk-Benefit Assessment of Ethinylestradiol Using a Physiologically Based Pharmacokinetic Modeling Approach. Clin Pharmacol Ther. 2018 Dec;104(6):1229-1239. doi: 10.1002/cpt.1085. Epub 2018 Apr 27.
6 Cargill DI, Steinetz BG, Gosnell E, Beach VL, Meli A, Fujimoto GI, Reynolds BM: Fate of ingested radiolabeled ethynylestradiol and its 3-cyclopentyl ether in patients with bile fistulas. J Clin Endocrinol Metab. 1969 Aug;29(8):1051-61. doi: 10.1210/jcem-29-8-1051.
7 Guo W, Reigan P, Siegel D, Ross D: Enzymatic reduction and glutathione conjugation of benzoquinone ansamycin heat shock protein 90 inhibitors: relevance for toxicity and mechanism of action. Drug Metab Dispos. 2008 Oct;36(10):2050-7. doi: 10.1124/dmd.108.022004. Epub 2008 Jul 17.
8 Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
9 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
10 ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.
11 17alpha-Ethinylestradiol hinders nucleotide excision repair in zebrafish liver cells. Aquat Toxicol. 2009 Dec 13;95(4):273-8.
12 P-glycoprotein (P-gp/MDR1)-mediated efflux of sex-steroid hormones and modulation of P-gp expression in vitro. Pharm Res. 2004 Jul;21(7):1284-93.
13 Rifampicin, a keystone inducer of drug metabolism: from Herbert Remmer's pioneering ideas to modern concepts. Drug Metab Rev. 2004 Oct;36(3-4):497-509.
14 The involvement of CYP3A4 and CYP2C9 in the metabolism of 17 alpha-ethinylestradiol. Drug Metab Dispos. 2004 Nov;32(11):1209-12.
15 Drug-drug interactions for UDP-glucuronosyltransferase substrates: a pharmacokinetic explanation for typically observed low exposure (AUCi/AUC) ratios. Drug Metab Dispos. 2004 Nov;32(11):1201-8.
16 The effect of ethinyloestradiol and levonorgestrel on the CYP2C19-mediated metabolism of omeprazole in healthy female subjects. Br J Clin Pharmacol. 2003 Aug;56(2):232-7.
17 Examination of 209 drugs for inhibition of cytochrome P450 2C8. J Clin Pharmacol. 2005 Jan;45(1):68-78.
18 The genomic response of a human uterine endometrial adenocarcinoma cell line to 17alpha-ethynyl estradiol. Toxicol Sci. 2009 Jan;107(1):40-55.
19 Differential effect of estrogen receptor alpha and beta agonists on the receptor for advanced glycation end product expression in human microvascular endothelial cells. Biochim Biophys Acta. 2005 Sep 30;1745(3):300-9. doi: 10.1016/j.bbamcr.2005.03.012. Epub 2005 Apr 12.
20 Friedman CI, Huneke AL, Kim MH, Powell J "The effect of ampicillin on oral contraceptive effectiveness." Obstet Gynecol 55 (1980): 33-7. [PMID: 7188714]
21 Bailey DG, Arnold JMO, Spence JD "Grapefruit juice and drugs - how significant is the interaction." Clin Pharmacokinet 26 (1994): 91-8. [PMID: 8162660]
22 Loi CM, Stern R, Koup JR, Vassos AB, Knowlton P, Sedman AJ "Effect of troglitazone on the pharmacokinetics of an oral contraceptive agent." J Clin Pharmacol 39 (1999): 410-7. [PMID: 10197300]
23 Gunston GD, Mehta U "Potentially serious drug interactions with grapefruit juice." S Afr Med J 90 (2000): 41. [PMID: 10721388]
24 Product Information. Cosentyx (secukinumab). Novartis Pharmaceuticals, East Hanover, NJ.
25 Product Information. Ambien (zolpidem). sanofi-aventis, Bridgewater, NJ.
26 Lazar JD, Wilner KD "Drug interactions with fluconazole." Rev Infect Dis 12 Suppl 3 (1990): s327-33. [PMID: 2330488]
27 Gardner MJ, Tornatore KM, Jusko WJ, Kanarkowski R "Effects of tobacco smoking and oral contraceptive use on theophylline disposition." Br J Clin Pharmacol 16 (1983): 271-80. [PMID: 6626419]
28 Edelbroek PM, Zitman FG, Knoppert-van der Klein EA, van Putten PM, de Wolff FA "Therapeutic drug monitoring of amitriptyline: impact of age, smoking and contraceptives on drug and metabolite levels in bulimic women." Clin Chim Acta 165 (1987): 177-87. [PMID: 3652444]
29 Cerner Multum, Inc. "Australian Product Information.".
30 Product Information. Turalio (pexidartinib). Daiichi Sankyo, Inc., Parsippany, NJ.
31 Product Information. Fycompa (perampanel). Eisai Inc, Teaneck, NJ.
32 Product Information. Tukysa (tucatinib). Seattle Genetics Inc, Bothell, WA.
33 Product Information. Lipitor (atorvastatin). Parke-Davis, Morris Plains, NJ.
34 Notelovitz M "Oral contraception and coagulation." Clin Obstet Gynecol 28 (1985): 73-83. [PMID: 3987135]
35 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
36 Lilja JJ, Kivisto KT, Neuvonen PJ "Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors." Clin Pharmacol Ther 64 (1998): 477-83. [PMID: 9834039]
37 Adson DE, Kotlyar M "A probable interaction between a very low-dose oral contraceptive and the antidepressant nefazodone: a case report." J Clin Psychopharmacol 21 (2001): 618-9. [PMID: 11763013]
38 Ito D, Amano T, Sato H, Fukuuchi Y "Paroxysmal hypertensive crises induced by selegiline in a patient with Parkinson's disease." J Neurol 248 (2001): 533-4. [PMID: 11499649]
39 Back DJ, Breckenridge AM, Crawford FE, MacIver M, Orne ML, Rowe PH "Interindividual variation and drug interactions with hormonal steroid contraceptives." Drugs 21 (1981): 46-61. [PMID: 7009137]
40 EMEA. European Medicines Agency "EPARs. European Union Public Assessment Reports.".
41 Back DJ, Grimmer SF, Orme ML, Proudlove D, Mann RD, Breckenridge AM "Evaluation of Committee on Safety of Medicines yellow card reports on oral contraceptive-drug interactions with anticonvulsants and antibiotics." Br J Clin Pharmacol 25 (1988): 527-32. [PMID: 3408633]
42 Product Information. Briviact (brivaracetam). UCB Pharma Inc, Smyrna, GA.
43 Fuhr U, Maier-Bruggemann A, Blume H, et al. "Grapefruit juice increases oral nimodipine bioavailability." Int J Clin Pharmacol Ther 36 (1998): 126-32. [PMID: 9562227]
44 Faculty of Sexual & Reproductive Healthcare "FSRH Clinical Guidance: Drug Interactions with Hormonal Contraception.".
45 Back DJ, Breckenridge AM, Crawford F, et al. "The effect of rifampicin on norethisterone pharmacokinetics." Eur J Clin Pharmacol 15 (1979): 193-7. [PMID: 37091]
46 Product Information. Orladeyo (berotralstat). BioCryst Pharmaceuticals Inc, Durham, NC.
47 Product Information. Accolate (zafirlukast). Zeneca Pharmaceuticals, Wilmington, DE.
48 Product Information. Retevmo (selpercatinib). Lilly, Eli and Company, Indianapolis, IN.
49 Product Information. Copiktra (duvelisib). Verastem, Inc., Needham, MA.
50 EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring.".
51 Product Information. Xeglyze (abametapir topical). Dr. Reddy's Laboratories Inc, Upper Saddle River, NJ.
52 Product Information. Zokinvy (lonafarnib). Eiger BioPharmaceuticals, Palo Alto, CA.
53 Product Information. Prograf (tacrolimus). Fujisawa, Deerfield, IL.
54 Product Information. Tavalisse (fostamatinib). Rigel Pharmaceuticals, South San Francisco, CA.